Protein Design Labs, Inc.

Nov 08, 07
	NEW STORY
16:47 ET	PDL BioPharma Announces Third Quarter 2007 Financial Results
Oct 11, 07
16:26 ET	Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
Oct 01, 07
16:02 ET	PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
Aug 28, 07
16:05 ET	PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Aug 20, 07
08:30 ET	PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
Aug 01, 07
16:30 ET	PDL BioPharma Announces Second Quarter 2007 Financial Results
Jul 31, 07
17:30 ET	Joseph Klein III Joins PDL's Board of Directors
Jul 18, 07
16:19 ET	PDL BioPharma Announces August 1 Webcast of Second Quarter Financial Results Conference Call
Jun 13, 07
17:58 ET	PDL BioPharma Announces Participation at the William Blair 27th Annual Growth Stock Conference and Webcast Presentation on June 21
May 22, 07
08:00 ET	PDL BioPharma Announces Long-Term Nuvion(R) Data Presented at 2007 Digestive Disease Week
May 18, 07
17:25 ET	PDL BioPharma Announces Participation at the Citigroup 2007 Healthcare Conference and Webcast Presentation on May 23
May 02, 07
21:26 ET	PDL BioPharma Announces Participation at the 2007 Deutsche Bank Health care Conference and Webcast Presentation on May 3
16:00 ET	PDL BioPharma Announces First Quarter 2007 Financial Results
Apr 27, 07
15:01 ET	PDL BioPharma Announces May 2 Webcast of First Quarter Financial Results Conference Call
Apr 26, 07
08:00 ET	PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study in Intravenous Steroid-Refractory Ulcerative Colitis
Apr 24, 07
10:34 ET	PDL BioPharma's European Patent Claims Upheld
Apr 09, 07
16:34 ET	PDL BioPharma Announces Election of L. Patrick Gage as Chairman of the Board
Mar 29, 07
16:13 ET	PDL BioPharma Names Bob Savel SVP of Technical Operations
Mar 14, 07
16:05 ET	PDL BioPharma Announces Participation at the Lehman Brothers Global Healthcare Conference and Webcast Presentation on March 19
Mar 12, 07
06:55 ET	Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
Mar 08, 07
13:08 ET	PDL BioPharma Announces Participation at the Cowen and Company 27th Annual Healthcare Conference and Webcast Presentation on March 15
Feb 21, 07
16:16 ET	PDL BioPharma Announces Fourth Quarter and Full Year 2006 Financial Results
Feb 20, 07
16:22 ET	PDL BioPharma Announces New Chief Medical Officer and Appoints Chief Scientific Officer to Its Board of Directors
Feb 14, 07
17:34 ET	PDL BioPharma Announces February 21 Webcast of Fourth Quarter and Year-End 2006 Financial Results Conference Call
Jan 08, 07
08:30 ET	PDL BioPharma Announces Participation at JP Morgan Healthcare Conference and Webcast Presentation on January 11
Dec 11, 06
16:45 ET	PDL BioPharma Presents Preclinical Data on Novel Monoclonal Antibody for Multiple Myeloma at the American Society of Hematology Annual Meeting
Nov 24, 06
08:00 ET	PDL BioPharma Announces Participation at Upcoming Lazard Investor Conference on November 28
Nov 21, 06
16:05 ET	PDL BioPharma Announces Roche to Discontinue Co-Development of Daclizumab
Nov 02, 06
16:05 ET	PDL BioPharma Announces Third Quarter 2006 Financial Results
Oct 25, 06
16:23 ET	PDL BioPharma Announces November 2 Webcast of Third Quarter 2006 Financial Results Conference Call
Oct 23, 06
03:00 ET	PDL BioPharma and The European Crohn's and Colitis Organization Collaborate to Support Global Clinical Trial Program for Severe IV Steroid Refractory Ulcerative Colitis
Oct 16, 06
09:58 ET	PDL BioPharma Announces Physician Survey Results on Heart Attack Treatment Presented at American College of Emergency Physicians Scientific Assembly
Oct 13, 06
15:01 ET	PDL BioPharma Announces Supplement to Prospectus for Resale of $250 Million Convertible Senior Notes Filed With the SEC
Sep 21, 06
10:03 ET	PDL BioPharma Announces Participation at Upcoming Investor Conferences
Sep 05, 06
18:51 ET	PDL BioPharma Announces Webcast of Presentation at Newsmakers in the Biotech Industry Conference
Aug 30, 06
08:30 ET	PDL BioPharma Announces Roche Discontinuation of Co-Development of Daclizumab in Asthma
Aug 28, 06
08:30 ET	PDL BioPharma Adopts Stockholder Rights Plan
Aug 03, 06
16:07 ET	PDL BioPharma Announces Second Quarter 2006 Financial Results
16:02 ET	PDL BioPharma Reports Results From Phase 3 Trial of Terlipressin In Type 1 Hepatorenal Syndrome
Jul 25, 06
08:30 ET	PDL BioPharma Announces August 3 Webcast of Second Quarter 2006 Financial Results Conference Call
Jul 06, 06
16:22 ET	PDL BioPharma Announces Mid-2007 Move of Corporate Headquarters in San Francisco Bay Area
Jun 09, 06
09:28 ET	PDL Announces Participation in Upcoming Investor Conferences
Jun 06, 06
08:00 ET	Clinical Data on Volociximab (M200) Presented at the American Society of Clinical Oncology Annual Meeting
May 24, 06
12:45 ET	New Data for Nuvion(R) Presented at Digestive Disease Week Conference
May 02, 06
16:05 ET	PDL BioPharma Announces First Quarter 2006 Financial Results
Apr 26, 06
18:36 ET	PDL BioPharma Announces Webcasts of First Quarter 2006 Financial Results Conference Call on May 2 and First Annual Business Update on May 5
Apr 24, 06
09:00 ET	PDL BioPharma Elects Brad Goodwin to Board of Directors
Mar 23, 06
16:09 ET	PDL BioPharma Reports Patient Enrollment Completed for Terlipressin Phase 3 Clinical Study
Mar 17, 06
08:56 ET	PDL BioPharma Releases Revised 2005 Financial Tables
Mar 07, 06
16:20 ET	PDL BioPharma Names Andrew Guggenhime Senior Vice President and Chief Financial Officer
Feb 28, 06
16:28 ET	PDL Announces Webcast of Presentation at Citigroup Global Healthcare Conference
Feb 27, 06
16:00 ET	PDL BioPharma Announces Fourth Quarter and Full Year 2005 Financial Results
Feb 22, 06
13:53 ET	PDL Biopharma Announces February 27 Webcast of Fourth Quarter and Year-End 2005 Financial Results Conference Call
Jan 24, 06
07:31 ET	'Wait and See' Approach to Heart Attack Warning Signs May Contribute to Poor Survival Rates
Jan 10, 06
07:00 ET	Human Genome Sciences Licenses Worldwide Intellectual Property Rights for Target Antigen to PDL BioPharma
Jan 09, 06
15:49 ET	Protein Design Labs Becomes PDL BioPharma
13:41 ET	PDL Announces Webcast of Presentation at 24th Annual JPMorgan Healthcare Conference
Jan 03, 06
16:00 ET	PDL Grants Patent Licenses to Merck for Humanized Antibodies Against Two Undisclosed Antigens
Nov 01, 05
16:00 ET	PDL Announces Third Quarter 2005 Financial Results
08:06 ET	Roche and Protein Design Labs to Jointly Develop Daclizumab in Transplant Maintenance Therapy
Oct 26, 05
08:01 ET	Protein Design Labs Announces November 1 Webcast of Third Quarter 2005 Financial Results Conference Call
Oct 04, 05
16:00 ET	Protein Design Labs Elects Samuel Broder, M.D. to Board of Directors
Oct 03, 05
16:00 ET	PDL Announces Webcast of R&D Update at 8 AM EDT on October 7
Sep 19, 05
16:00 ET	Protein Design Labs Names Dr. Peter Calcott Vice President, Quality And Compliance
Sep 15, 05
16:00 ET	PDL Announces Senior Management Changes
Sep 12, 05
16:00 ET	PDL Announces Successful Closing of Global Alliance With Biogen Idec to Develop and Commercialize Three Phase II Antibody Products
Sep 04, 05
06:30 ET	Phase 2 Ularitide Study Highlighted at European Society of Cardiology Congress
Aug 11, 05
16:36 ET	Registration Statement for Resale of $250 Million Convertible Senior Notes Declared Effective by SEC
Aug 04, 05
19:32 ET	PDL Announces Strong Second Quarter 2005 Financial Results
16:09 ET	PDL Announces Strong Second Quarter 2005 Financial Results
Aug 02, 05
16:03 ET	Biogen Idec and PDL Form Global Alliance to Develop and Commercialize Three Phase II Antibody Products
Jul 28, 05
20:21 ET	Protein Design Labs Announces August 4 Webcast of Second Quarter 2005 Financial Results Conference Call
Jun 22, 05
08:02 ET	Protein Design Labs Sublicenses Rights to Develop Antibody-Drug Conjugates for Prostate Cancer to Genentech, Inc.
May 24, 05
16:30 ET	Protein Design Labs Announces Webcast of Nuvion(R) (Visilizumab) Clinical Development Update at 4:30 p.m. Eastern Time, May 31
May 02, 05
16:04 ET	Protein Design Labs Announces First Quarter 2005 Financial Results
Apr 27, 05
17:30 ET	Protein Design Labs Announces May 2 Webcast of First Quarter 2005 Financial Results Conference Call
Apr 20, 05
16:09 ET	Protein Design Labs and Orphan Therapeutics Report Fast Track Designation for Terlipressin in Type 1 Hepatorenal Syndrome
Apr 18, 05
08:00 ET	Protein Design Labs Reports Positive Results in Phase II Clinical Trial (SIRIUS II) of Ularitide for Decompensated Congestive Heart Failure
Mar 24, 05
08:01 ET	Protein Design Labs Completes Acquisition of ESP Pharma and Retavase Product
Mar 23, 05
08:02 ET	Protein Design Labs Reports on Nuvion(R) (Visilizumab) End of Phase I Meeting Held With the FDA
Mar 14, 05
16:00 ET	Protein Design Labs Announces Above Consensus Full-Year and Fourth Quarter 2004 Financial Results and Provides 2005 Update and Guidance
Feb 28, 05
08:03 ET	Protein Design Labs Announces March 14 Webcast of Full Year and Fourth Quarter 2004 Financial Results Conference Call
Feb 16, 05
08:02 ET	Protein Design Labs Completes Placement of $250 Million of Convertible Senior Notes
Feb 09, 05
08:00 ET	Protein Design Labs to Receive $250 Million From Offering of Convertible Senior Notes
Feb 07, 05
16:03 ET	Protein Design Labs Announces Intent to Offer $250 Million of Convertible Senior Notes in Private Offering
Feb 02, 05
16:02 ET	Protein Design Labs Announces Ruling in European Patent Opposition Proceeding
Feb 01, 05
08:05 ET	PDL to Adjust Purchase Price for ESP Pharma, Inc. Following ESP Pharma's Acquisition of Rights to Retavase(R)
Jan 25, 05
08:03 ET	PDL to Acquire ESP Pharma, Inc.
Jan 12, 05
08:03 ET	PDL Updates Status of Clinical Development Programs and Partnering Objectives
Nov 01, 04
16:00 ET	Protein Design Labs Announces Third Quarter 2004 Financial Results
Oct 28, 04
16:13 ET	Protein Design Labs Announces Webcast of Third Quarter Financial Results Conference Call
Oct 11, 04
16:00 ET	Protein Design Labs Announces Webcast of R&D Update at 8:00 a.m. Eastern Time, October 15
Oct 06, 04
08:00 ET	Protein Design Labs Presents Preclinical Data on Anti-Alpha5Beta1 Integrin Antibody Fragment at Retina Society Meeting
Sep 29, 04
08:01 ET	Protein Design Labs Presents Interim Clinical Data From Phase I Trial of Anti-Alpha5beta1 Integrin Antibody (M200) in Patients With Solid Tumors Refractory to Standard Treatment
08:01 ET	Protein Design Labs Presents Interim Findings From Nuvion(R) Phase I / II Trial in Severe Ulcerative Colitis
Sep 16, 04
01:30 ET	Roche and Protein Design Labs to Jointly Develop Zenapax(R) for Asthma
Sep 08, 04
07:30 ET	Protein Design Labs to Host R&D Update Meeting in New York on October 15
Aug 09, 04
09:01 ET	Enrollment Continues in Retreatment Phase of Phase I/II Clinical Trial of Nuvion(R) in Patients With Severe Ulcerative Colitis
Aug 03, 04
21:29 ET	Protein Design Labs Announces Second Quarter 2004 Financial Results
Jul 27, 04
19:30 ET	Protein Design Labs Announces Webcast of Second Quarter Financial Results Conference Call
Jul 19, 04
08:02 ET	Protein Design Labs and Morphotek Announce Broad, Multi-Year Research Cross-License and Commercialization Agreement
Jun 30, 04
16:00 ET	Dr. Max Link Elected Chairman of the Board of Protein Design Labs
Jun 10, 04
08:00 ET	Protein Design Labs Names Three Executives to New Management Positions
May 16, 04
12:00 ET	Protein Design Labs Reports Negative Results in Phase II Clinical Trial of Daclizumab in Ulcerative Colitis
May 13, 04
08:01 ET	Protein Design Labs Announces Webcast on May 19 at 11 a.m. Eastern Time to Discuss Programs in Inflammatory Bowel Disease
May 10, 04
16:01 ET	Protein Design Labs Launches Expanded Corporate Web Site
May 04, 04
16:00 ET	Protein Design Labs Announces First Quarter 2004 Financial Results
Apr 27, 04
16:38 ET	Protein Design Labs Announces Webcast of First Quarter Financial Results Conference Call
Apr 21, 04
16:02 ET	Protein Design Labs Announces Webcast of Presentation at CIBC World Markets Biotechnology and Specialty Pharmaceuticals Conference at 1:45 p.m. Eastern Time, April 27
Mar 22, 04
07:03 ET	Protein Design Labs Reports Progress on Two Humanized Antibodies at International Organization of Inflammatory Bowel Disease
Mar 15, 04
08:08 ET	Protein Design Labs Reports Positive Results in Phase II Clinical Trial Of Daclizumab in Asthma
Feb 26, 04
16:01 ET	Protein Design Labs Announces Full-Year and Fourth Quarter 2003 Financial Results
Feb 20, 04
16:00 ET	Protein Design Labs Announces Webcast of Full-Year and Fourth Quarter Financial Results Conference Call
07:45 ET	Protein Design Labs Announces Webcast of Full-Year and Fourth Quarter Financial Results Conference Call
Feb 19, 04
16:03 ET	Protein Design Labs Announces Publication of Research Showing Extended Half-Lives of Antibodies
Jan 26, 04
08:01 ET	Protein Design Labs Receives License Fees for Xolair(R) and Raptiva(TM) Antibody Products
Jan 12, 04
16:00 ET	Xencor and Protein Design Labs Initiate Partnership for Optimized Antibodies
Jan 09, 04
11:30 ET	Protein Design Labs Announces Webcast of R&D Day at 2:30 p.m. Eastern Time, January 15
Dec 23, 03
16:00 ET	Abbott Laboratories Licenses Protein Design Labs' Intellectual Property for Antibodies Binding to Interleukin-12 (IL-12) and the IL-12 Receptor
Dec 22, 03
08:01 ET	Genentech and Protein Design Labs Settle Patent License Dispute
Dec 12, 03
15:15 ET	Registration Statement for Resale of $250 Million Convertible
Dec 11, 03
08:02 ET	Protein Design Labs Begins Phase I/II Clinical Trial of Visilizumab (Nuvion(R)) in Severe Ulcerative Colitis
Dec 01, 03
08:03 ET	Genentech and Protein Design Labs Agree in Principle To Resolve Patent License Dispute
08:03 ET	Protein Design Labs Announces Webcast To Discuss Status Of Patent License Dispute
Nov 12, 03
16:00 ET	PDL'S Appeal of Patent Opposition Upheld By European Technical Board of Appeal
Nov 03, 03
16:00 ET	Protein Design Labs Announces Third Quarter 2003 Financial Results
Oct 27, 03
16:00 ET	Protein Design Labs Announces Webcast of Third Quarter Conference Call
Oct 02, 03
08:02 ET	ARIUS Research and Protein Design Labs, Inc. Sign Agreement For Expanded Collaboration
Sep 30, 03
08:02 ET	Roche and Protein Design Labs Restructure Commercial Alliance on Zenapax(R)
Sep 29, 03
08:02 ET	Protein Design Labs to Redeem Outstanding 5.50% Convertible Notes
Sep 19, 03
08:01 ET	Protein Design Labs and Genentech Extend Patent Licensing Master Agreement
Aug 15, 03
08:01 ET	Protein Design Labs Reports on Status of Genentech Humanization Patent License Arrangement
Aug 14, 03
08:02 ET	Protein Design Labs Announces Adjustment in Second Quarter 2003 Financial Results
Jul 29, 03
16:00 ET	Protein Design Labs Announces Second Quarter 2003 Financial Results
Jul 21, 03
16:00 ET	Protein Design Labs Announces Webcast of Second Quarter Conference Call
16:00 ET	Protein Design Labs Announces Webcast of Second Quarter Conference Call
Jul 08, 03
19:00 ET	Protein Design Labs Prices $250 Million Convertible Subordinated Notes Offering
Jul 07, 03
16:01 ET	Protein Design Labs Announces Intent to Offer $200 Million of Convertible Subordinated Notes in Private Offering
Jun 26, 03
08:30 ET	Karen A. Dawes Elected a Director of Protein Design Labs
Jun 23, 03
08:31 ET	Protein Design Labs Updates Status of Genentech Humanization Patent License Arrangement
Jun 02, 03
08:02 ET	Protein Design Labs Begins Trial of Anti-a5B1 Integrin Antibody in Solid Tumors
May 19, 03
08:02 ET	Protein Design Labs Reports Progress with Three Humanized Antibodies in Inflammatory Bowel Disease
May 13, 03
16:00 ET	Protein Design Labs Announces Webcast to Discuss R&D Strategy and Clinical Data in Inflammatory Bowel Disease
May 08, 03
07:00 ET	Protein Design Labs Says It Has Stopped Development of Anti-IL-4 Antibody Following Phase II Results
May 06, 03
06:01 ET	Protein Design Labs Names Glen Y. Sato Chief Financial Officer
Apr 29, 03
16:01 ET	Protein Design Labs Reports First Quarter 2003 Financial Results
Apr 22, 03
16:03 ET	Protein Design Labs Announces Webcast of First Quarter Conference Call
Apr 07, 03
08:03 ET	Protein Design Labs Completes Acquisition of Eos Biotechnology, Inc.
Mar 27, 03
08:00 ET	L. Patrick Gage, Ph.D., Joins Protein Design Labs' Board of Directors
Mar 18, 03
08:01 ET	Protein Design Labs Licenses Development Rights to SMART(TM) M195 Antibody To Actinium Pharmaceuticals
Feb 26, 03
16:00 ET	Protein Design Labs Reports Full-Year And Fourth Quarter 2002 Financial Results
Feb 19, 03
16:01 ET	Protein Design Labs Announces Webcast of Fourth Quarter and Year-End Conference Call
Feb 04, 03
16:00 ET	Protein Design Labs to Acquire Eos Biotechnology, Inc.
Jan 06, 03
16:00 ET	Protein Design Labs Announces Agreement With MedImmune for Humanized Antibody Patent Rights and Updates Financial Guidance
16:00 ET	Protein Design Labs Outlines Initiatives for Next Stages of Growth
15:30 ET	Protein Design Labs to Present Tuesday, January 7, 9:30 a.m., At J.P. Morgan Chase & Co. Healthcare Conference
Jan 02, 03
17:36 ET	Protein Design Labs Announces Webcasts Hosted by New Management Team to Discuss Research, Clinical Development Programs and Initial Strategy Changes
Nov 07, 02
16:00 ET	Protein Design Labs Announces Third Quarter 2002 Financial Results
08:01 ET	Protein Design Labs Names Steven E. Benner, M.D., M.H.S., Senior Vice President and Chief Medical Officer
Nov 05, 02
08:01 ET	Protein Design Labs Announces Mark McDade as Its New Chief Executive Officer And Director
Oct 31, 02
16:00 ET	Protein Design Labs Announces Webcast of Third Quarter Conference Call
Aug 07, 02
16:00 ET	Protein Design Labs Announces Second Quarter 2002 Financial Results
Jul 31, 02
16:00 ET	Protein Design Labs Announces Webcast of Second Quarter Conference Call
Jul 11, 02
08:32 ET	Igeneon Licenses Humanized Antibody in Cancer From Protein Design Labs
Jul 09, 02
16:00 ET	Protein Design Labs Begins Phase I Clinical Trial of Nuvion(R) in Ulcerative Colitis
Jun 26, 02
16:00 ET	Protein Design Labs Begins Phase I Clinical Trial Of SMART(R) Anti-IL-12 Antibody
May 21, 02
16:00 ET	Protein Design Labs Presents Phase I/II Clinical Results With SMART(R) Anti-Gamma Interferon Antibody in Crohn's Disease
May 19, 02
11:00 ET	Protein Design Labs Presents Data From Phase III Trial Of Zamyl(TM) in Acute Myeloid Leukemia
May 14, 02
16:00 ET	Protein Design Labs Begins Phase I Trial of Remitogen(TM) in Cancer Patients With Solid Tumors
May 09, 02
16:00 ET	Protein Design Labs Reports First Quarter 2002 Financial Results
May 08, 02
16:00 ET	Protein Design Labs Begins Phase II Trial of SMART(R) Anti-Gamma Interferon Antibody in Crohn's Disease
May 02, 02
16:00 ET	Protein Design Labs Announces Webcast of First Quarter Conference Call
May 01, 02
16:39 ET	Protein Design Labs Announces Resignation of Daniel J. Levitt, M.D., Ph.D., As President, Research and Development
16:36 ET	Laurence Jay Korn, Ph.D., Relinquishes Role as Chief Executive Officer Of Protein Design Labs; Douglas O. Ebersole to Serve as Interim Chief Executive Officer
Mar 26, 02
16:00 ET	Brett Schmidli Joins Protein Design Labs as Senior Vice President, Technical Operations
Mar 20, 02
16:00 ET	Protein Design Labs Announces Results of Phase II Clinical Trial Of Zenapax(R) in Psoriasis
Mar 11, 02
16:00 ET	Protein Design Labs Begins Phase II Trial of Nuvion(TM) In Steroid-Refractory Graft-Versus-Host Disease
Feb 28, 02
16:00 ET	Protein Design Labs Reports Full-Year and Fourth Quarter 2001 Financial Results
Feb 21, 02
16:00 ET	Protein Design Labs Announces Webcast of Fourth Quarter and Year-End Conference Call
Dec 19, 01
16:00 ET	Protein Design Labs Grants License to Celltech Under Patent Agreement
Dec 10, 01
05:00 ET	Protein Design Labs Reports Preliminary Data in Phase II Trial OF Remitogen(TM)
Dec 07, 01
05:00 ET	Protein Design Labs Announces Positive Phase III Clinical Results With Zamyl(TM) for Acute Myeloid Leukemia; Plans to File BLA
Nov 30, 01
13:00 ET	Protein Design Labs Announces Webcast of Conference Call at Hematology Meeting
Nov 26, 01
16:00 ET	Protein Design Labs Begins Phase II Trial of Zenapax in Patients With Chronic Asthma
Nov 05, 01
06:00 ET	Protein Design Labs Announces Promising Preliminary Clinical Results With SMART(TM) Anti-Gamma Interferon; Plans Additional Development
Nov 01, 01
16:00 ET	Protein Design Labs Announces Third Quarter 2001 Financial Results
Oct 29, 01
06:00 ET	Protein Design Labs Announces Phase I Trial of Remitogen(TM) in Combination With Rituxan(R) in Cancer Patients
Oct 25, 01
16:02 ET	Protein Design Labs Announces Webcast of Third Quarter Conference Call
Oct 09, 01
16:00 ET	Protein Design Labs Begins Phase II Study Of Humanized Anti-IL-4 Antibody In Asthma
Aug 30, 01
16:00 ET	Lyn D. Olson, Ph.D. and Mark P. Backer, Ph.D. Join Protein Design Labs as Vice Presidents; Sergio Garcia-Rodriguez Appointed Vice President, Legal and General Counsel
Aug 28, 01
16:00 ET	Protein Design Labs Announces Two-for-One Stock Split
Aug 02, 01
16:00 ET	Protein Design Labs Announces Second Quarter 2001 Financial Results
Jul 26, 01
13:00 ET	Protein Design Labs Announces Webcast of Second Quarter Conference Call
Jul 10, 01
16:00 ET	Protein Design Labs Announces Patent Rights Agreement With American Home Products
Jun 22, 01
08:00 ET	Protein Design Labs Presents Three Humanized Antibodies in Clinical Development for Psoriasis at International Psoriasis Symposium
May 22, 01
16:00 ET	Protein Design Labs and Exelixis Announce Oncology Antibody Drug Discovery Collaboration
May 14, 01
16:00 ET	Protein Design Labs Announces First Quarter 2001 Financial Results
May 07, 01
15:00 ET	Protein Design Labs Announces Webcast of First Quarter Conference Call
May 02, 01
16:00 ET	Protein Design Labs Announces Development of SMART(TM) Anti-IL-12 Antibody
Mar 20, 01
16:05 ET	Protein Design Labs Announces Phase I Results With Humanized Anti-IL-4 Antibody in Asthma
Feb 20, 01
16:06 ET	Protein Design Labs Announces Phase II Trial of SMART 1D10 Antibody In Non-Hodgkin's Lymphoma
Feb 13, 01
16:05 ET	Protein Design Labs Announces Positive Full Year 2000 Financial Results
Feb 07, 01
12:30 ET	Protein Design Labs Announces Webcast of Fourth Quarter and Year-End Conference Call
Jan 30, 01
16:05 ET	Protein Design Labs Granted Fourth Antibody Humanization Patent In the United States